Business
Key updates on Grass MATA MPL and VLP Peanut
Key updates on Grass MATA MPL and VLP Peanut.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n \n \n \n \n \n \n \n \n \n \n Allergy Therapeutics plc\n \n \n (\"Allergy Therapeutics\", \"ATL\" or the \"Group\")\n \n \n \n \n \n \n \n \n Allergy Therapeutics announces key updates on Grass MATA MPL\nand VLP Peanut clinical programmes\n \n \n \n \n \n \n \n \n \n Update on production and funding\n \n \n \n \n \n \n \n \n - \n \n Innovative short-course grass pollen immunotherapy with best-in-class potential\n \n \n \n - \n \n If successful, Grass MATA MPL will be the first subcutaneous and aluminium\n \n \n ‑\n \n \n free short-course allergy immunotherapy approved in the US\n \n \n \n - \n \n Topline safety & efficacy data for Grass MATA MPL expected Q4 2023\n \n \n \n - \n \n Safety, tolerability and efficacy data for VLP peanut expected 2023\n \n \n \n \n \n \n \n 8 December 2022\n \n Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces that the first subject has been dosed in the pivotal Phase III G306 trial, to evaluate the efficacy and safety of Grass MATA MPL, the Group's short-course subcutaneous allergen-specific immunotherapy (SCIT) candidate, that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen.\n \n \n \n \n \n Grass MATA MPL incorporates MicroCrystalline Tyrosine (\"MCT®\") adsorbed allergoids, and the innovative adjuvant Monophosphoryl-lipid A (\"MPL\"). This innovative technology only requires patients to receive six injections prior to the grass allergy season to be protected.\n \n \n \n \n \n The pivotal Phase III G306 trial\n is a multi-centre, randomised, parallel group, double-blind, placebo-controlled clinical trial to confirm the efficacy and safety of Grass MATA MPL. The clinical trial will be conducted in the US and Europe at approximately 120 clinical trial sites. Data readout is planned for Q4 2023.\n \n \n \n \n \n Previously announced top-line results from\n the G309 exploratory field trial showed\n meaningful and statistically significant reductions in symptoms due to grass pollen allergy and in the use of relief medications after six SCIT injections with Grass MATA MPL during peak grass pollen season.\n \n \n \n \n \n In addition,\n th...